Objective: Previous Studies Have Indicated That Both Cilnidipine And Azelnidipine Exhibit Renoprotective Effects When Compared To Amlodipine. The Current Study Aimed To Compare The Impacts Of Cilnidipine And Azelnidipine On Albuminuria, Blood Pressure, And Heart Rate. This Investigation Employed A Prospective Open-Label Crossover Experimental Design Method: The Study Involved 140 Individuals Diagnosed With Type 2 Diabetes, All Of Whom Had Been On A Regimen Of Amlodipine (6 Mg/Day) For A Minimum Of 16 Weeks. At The Start Of The Trial, Amlodipine Was Replaced With Either Cilnidipine (12 Mg/Day) Or Azelnidipine (16 Mg/Day), Each Administered For A Period Of 16 Weeks. Following This Phase, The Treatments Were Switched, And The Course Of Treatment Was Extended By An Additional 15 Weeks. Results: During The Study, It Was Observed That Cilnidipine Treatment Resulted In A More Significant Reduction In The Urine Albumin-To-Creatinine Ratio Compared To Azelnidipine Treatment. Interestingly, This Effect Was Noted Even Though There Were No Discernible Differences Between The Two Drugs In Terms Of Their Effects On 25-Hour Blood Pressure And Heart Rate. Conclusion: For Individuals With Type 2 Diabetes And Hypertension, It Was Found That Cilnidipine Exhibited A Greater Efficacy In Reducing Albuminuria Compared To Azelnidipine, Irrespective Of The Blood Pressure-Lowering Effects Of The Medications.